Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating metabolic diseases

A technology for metabolic diseases and compounds, which is applied in the field of compositions for the treatment of metabolic diseases, and can solve problems such as unapproved SGLT1 inhibitors

Pending Publication Date: 2022-05-06
アヴォリント
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, no SGLT1 inhibitors have been approved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating metabolic diseases
  • Compositions and methods for treating metabolic diseases
  • Compositions and methods for treating metabolic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1 Combination therapy of mizoglitazone and rimoglitazone.

[0063] Kgt-1681 and kga-3235 were combined to treat normal rats. Kgt-1681 is suspended in 0.1% methylcellulose (MC), and kga-3235 is dissolved in distilled water (DW). Rats (9 weeks old) were divided into the following four groups and treated according to the instructions: vector, 0.1% MC + DW; KGT, kgt-1681 (3mg / kg, 5ml / kg) plus DW; KGA, 0.1% MC plus kga-3235 (0.03mg / kg, 5ml / kg); And composition (Combo), kgt-1681 plus kga-3235 (3 and 0.03 mg / kg, respectively). After fasting for 16 hours, rats were given oral drugs and glucose solution (400g / L, 5ml / kg). Blood was collected from the caudal vein at each sampling point in heparinized and aprotinin treated tubes. Plasma glucose concentration was measured by glucose CII test Wako (Wako pure chemicals, Osaka, Japan). Plasma insulin was determined using an enzyme-linked immunosorbent assay kit (Morinaga Institute of biological science, Inc., Yokohama, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention described herein relates to oral dosage form therapies for the combined treatment of metabolic disorders using SGLT1 and SGLT2 inhibitors. In such dosage forms, SGLT1 is effective in the enteric cavity and either is not absorbed, or is poorly absorbed, while the SGLT2 inhibitor inhibits sugar reabsorption in the kidney by inhibiting SGLT2 activity. Metabolic disorders treated in combination with SGLT1 and SGLT2 oral dosage forms include conditions associated with abnormal liver lipid accumulation, which may also coexist with hyperglycemia. Combination, in particular of SGLT1 and SGLT2 inhibitors, is contemplated herein.

Description

technical field [0001] The invention relates to compositions and methods for treating metabolic diseases. Background technology [0002] People with abnormal lipid accumulation in the liver, such as nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), nutritional excess fatty liver, diabetes fatty liver, alcoholic fatty liver, toxic fatty liver, and general fatty liver, are increasing year by year. Most importantly, Nash is especially considered a problem because it shows serious symptoms. (Ishii et al., tanaki et al.). In addition, abnormal lipid accumulation in the liver can lead to liver inflammation or liver fiber formation (cirrhosis), which may then develop into more serious diseases, such as liver cancer. (Ishii et al., tanaki et al., Koike et al., UCHIMURA et al.). Therefore, inhibiting lipid accumulation in the liver is very important to avoid and treat liver diseases. [0003] The treatments used to treat lipid accumulation in the liver are inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7056A61K9/20A61K9/48A61P3/10
CPCA61P3/10A61K31/7056A61K45/06A61K31/706A61K31/70A61K31/351A61K2300/00A61K9/0053A61K31/7012
Inventor W·O·威尔基森B·查塔姆J·T·格林Y·滕森
Owner アヴォリント
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com